A concerning trend is emerging in public health: a marked increase in colorectal cancer diagnoses among young adults. Historically considered a disease of older individuals, this type of cancer is now affecting people under the age of 50. This shift is prompting investigation from researchers and healthcare professionals in countries like France, as traditional risk factors such as poor diet, a sedentary lifestyle, and smoking don’t fully explain the change.
Now, new scientific advancements may offer an explanation. The rise in colorectal cancer among younger people could be linked to a toxin present in our intestines, produced by a common bacterium previously considered harmless. This toxin, called colibactin, may be a key element in this troubling phenomenon.
Colibactin: The Prime Suspect
Colibactin is a toxin produced by certain strains of Escherichia coli (E. Coli), a bacterium naturally found in the human gut microbiome. While most E. Coli strains are harmless, some, those carrying the pks gene, can produce this toxin, which is capable of disrupting human DNA.
A recent study published in Nature revealed that colibactin could be responsible for genetic mutations directly linked to the development of colorectal cancer. An international team of researchers analyzed the DNA of 981 colorectal tumors from patients in 11 different countries. By searching for specific mutation signatures, scientists discovered a striking correlation between certain genetic alterations and the presence of colibactin. This finding is significant as it points to a potential biological driver of the disease.
The study’s results show that the genetic signature of colibactin is more frequent in young patients with colorectal cancer. Specifically, mutations caused by this toxin were 3.3 times more prevalent in individuals under 40 compared to those over 70, suggesting a direct link between the toxin and the increase in early-onset colorectal cancers.
Early Exposure?
Alarmingly, researchers suspect this toxin may be present in our bodies from early childhood. The exposure to colibactin may not develop in adulthood, but rather initiate during youth.
Colibactin can cause DNA mutations in human cells by interfering with their genetic structure. If this toxin is present in the gut for an extended period—particularly during childhood—it could, over time, cause mutations in intestinal cells, increasing the risk of colorectal cancer earlier in life. A concerning aspect of this is that individuals may not show any obvious signs of damage for years, making detection difficult.
This too raises the question of whether environmental factors, such as diet, could play a role in activating these colibactin-producing strains of E. Coli. Changes in the modern diet, rich in fats and sugars, could promote the implantation and proliferation of these pathogenic strains, increasing risks.
Toward Targeted Prevention?
Although this discovery is recent, it opens interesting avenues for the prevention and early detection of colorectal cancer in young people. Identifying colibactin as a potential risk factor could lead to the development of new strategies to prevent these cancers at a younger age.
First, detecting E. Coli strains that produce colibactin could become a new tool for early diagnosis. A test to identify this toxin in stool or the gut could help identify at-risk individuals earlier, before the onset of symptoms. Early detection is crucial for improving treatment outcomes.
Next, it may be possible to explore approaches to modify the gut microbiome of at-risk individuals, using probiotics or specific antimicrobial treatments to eliminate pathogenic E. Coli strains that produce colibactin. Another interesting avenue would be the use of treatments designed to inhibit the action of colibactin, to limit its mutagenic impact.
Finally, colorectal cancer screening recommendations may need to be revised to include earlier exams, particularly for young adults with risk factors. Currently, systematic screening generally begins at age 50. If colibactin is indeed a risk factor, it would be relevant to lower this age limit.
A Silent Revolution in Cancer Research
This discovery represents a turning point in understanding the causes of the increase in early-onset colorectal cancers. It prompts us to rethink how the gut microbiome can affect our long-term health, and particularly its role in triggering early cancers.
Although the research is still in its early stages, highlighting the possible role of colibactin offers promising avenues for future research and treatments. It could also transform strategies for preventing colorectal cancer, allowing us to identify risks in childhood, rather than in adulthood.
As one of the study’s lead researchers noted:
“We knew that colorectal cancer was increasing in young people, but we didn’t know why. Now, we have a lead.”
, in the near future, this lead will result in concrete solutions to curb this silent epidemic.
